Table 1. Baseline characteristics of the patients in the different CTLA-4 and CD28 groups.
| Tumor CTLA-4 low expression(n = 93) | Tumor CTLA-4 high expression(n = 98) | p value | Lymphocyte CTLA-4 low expression(n = 90) | Lymphocyte CTLA-4 high expression(n = 101) | p value | Tumor CD28 low expression(n = 65) | Tumor CD28 high expression(n = 126) | p value | Lymphocyte CD28 lowe xpression(n = 95) | Lymphocyte CD28 high expression(n = 96) | p value | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age [mean (range)] | 47.5 (19–79) | 50.4 (20–78) | 0.115 | 48.6 (19–79) | 49.3 (20–78) | 0.704 | 48.7 (25–79) | 49.5 (19–76) | 0.824 | 48.4 (20–79) | 49.6 (19–76) | 0.498 |
| Age | ||||||||||||
| ≥ 50 | 41 | 55 | 0.096 | 41 | 55 | 0.219 | 33 | 63 | 0.920 | 47 | 49 | 0.828 |
| < 50 | 52 | 43 | 49 | 46 | 32 | 63 | 48 | 47 | ||||
| Sex | 0.219 | 0.261 | 0.462 | 0.157 | ||||||||
| Male | 68 (73.1%) | 79 (80.6%) | 66 (73.3%) | 81 (80.2%) | 48 (73.8%) | 99 (78.6%) | 69 (72.6%) | 78 (81.3%) | ||||
| Female | 25 (26.9%) | 19 (19.4%) | 24 (26.7%) | 20 (19.8%) | 17 (26.2%) | 27 (21.4%) | 26 (27.4%) | 18 (18.8%) | ||||
| Stage | 0.047 | 0.803 | 0.088 | 0.225 | ||||||||
| I II III IVa or IVb |
4 (4.3%) 13 (14.0%) 39 (41.9%) 34 (36.6%) |
1 (1.0%) 9 (9.2%) 39 (39.8%) 40 (40.8%) |
1 (1.1%) 11 (12.2%) 39 (43.3%) 34 (37.8%) |
4 (4.0%) 11 (10.9%) 39 (38.6%) 40 (39.6%) |
1 (1.5%) 11 (16.9%) 29 (44.6%) 21 (32.3%) |
4 (3.2%) 11 (8.7%) 49 (38.9%) 53 (42.1%) |
2 (2.1%) 13 (13.7%) 42 (44.2%) 32 (33.7%) |
3 (3.1%) 9 (9.4%) 36 (37.5%) 42 (43.8%) |
||||
| IVc | 3 (3.2%) | 9 (9.2%) | 5 (5.6%) | 7 (6.9%) | 3 (4.6%) | 9 (7.1%) | 6 (6.3%) | 6 (6.3%) | ||||
| WHO type | 0.727 | 0.003 | 0.218 | 0.399 | ||||||||
| II III |
2 (2.2%) 91 (97.8%) |
4 (4.1%) 94 (95.9%) |
0 90 (100.0%) |
6 (5.9%) 95 (94.1%) |
3 (4.6%) 62 (95.4%) |
3 (2.4%) 123 (97.6%) |
4 (4.2%) 91 (95.8%) |
2 (2.1%) 94 (97.9%) |
Abbreviations: WHO = World Health Organization.